Efficacy and safety of total glucosides of paeony in the treatment of systemic lupus erythematosus: A systematic review and meta-analysis

作者：Xiaohong Gong, Huan Li, Hongtao Guo, Shangwen Wu, Chaoqun Lu, Yi‐Ming Chen, Songwei Li · 发表于：Frontiers in Pharmacology · 年份：2022 · DOI：10.3389/fphar.2022.932874 · 被引用次数：11 · 研究领域：Systemic Lupus Erythematosus Research、Atherosclerosis and Cardiovascular Diseases、Immune Cell Function and Interaction

Background: Total glucosides of paeony (TGP), extracted from the Chinese medicine Paeonia lactiflora Pall., have been proven to be effective in various autoimmune diseases. We aim to systematically evaluate the efficacy and safety of TGP combined with different conventional therapeutic agents in the treatment of systemic lupus erythematosus (SLE). Methods: Eight databases were searched for randomized controlled studies of TGP for SLE. The search time was set from the establishment of the databases to March 2022. The risk of bias was assessed by the Cochrane Evaluation Manual (5.1.0), RevMan 5.3 software was used for meta-analysis, and the certainty of the evidence was assessed by the GRADE methodology. Results: A total of 23 articles were included, including 792 patients overall in the treatment group and 781 patients overall in the control group. The meta-analysis results showed that TGP combined with conventional treatments was superior to the conventional treatments in reducing the SLE disease activity and the incidence of adverse reactions (SMD TGP+GC+CTX = −1.98, 95% Cl = [−2.50, −1.46], p < 0.001; SMD TGP+GC+HCQ = −0.65, 95% Cl = [−1.04, −0.26], p <0.001; SMD TGP+GC+TAC = −0.94, 95% Cl = [−1.53, -0.34], p < 0.05; SMD TGP+GC = −1.00, 95% Cl = [−1.64, −0.36], p < 0.05; and RR TGP+GC+CTX = 0.37, 95% Cl = [0.21, 0.64], p < 0.001). The results also showed that TGP helped improve other outcomes related to SLE disease activity, such as comple...